Pharma Index Surges as Investors Pivot to Resilient Sector Amid Market Volatility
The Indian pharmaceutical sector demonstrated strong resilience on July 14, as investors increasingly rotated into pharmaceuticals and related healthcare companies. The Nifty Pharma index rose nearly 1%, effectively providing a hedge against risks associated with volatile crude oil prices and monsoon uncertainties affecting other sectors.Sector Performance Outperforms Benchmarks
Trading at 2:15 pm on July 14, the Nifty Pharma index stood at 25,873, registering a gain of 0.9%. This positive performance contrasted sharply against benchmark indices which were trading lower by 0.7%.Leading the sectorial ascent was Biocon, which rose 6.5%, followed by Divi's Labs gaining 3% and Gland Pharma climbing 1.5%. Major established players like Cipla, Sun Pharmaceutical Industries, and Dr. Reddy’s Laboratories also reported gains of 1-2% within the Nifty 50 constituents.
Biocon Stock Surges as Mylan Announces Secondary Sale
Shares of Biocon witnessed a significant surge, rising nearly 8% to reach Rs 442.60, marking an over-five-year high for the company. This sharp rally followed news that Mylan, part of global healthcare firm Viatris, intends to sell up to 92 million shares of Biocon.The secondary sale is valued at up to Rs 3,481 crore and represents up to 5.64% of Biocon's outstanding shares, according to Reuters reporting. It is important to note that this transaction is a secondary sale, meaning the proceeds will be received by the existing investor rather than Biocon itself.
Global Growth Trends and Domestic Opportunities for Pharma
The Indian pharmaceuticals market has reported robust growth, with sales surpassing 13% on-year in June, according to Nomura data, which cited it as the highest recorded growth since October-2023. This positive trend underlines the sector's sustained momentum.HDFC Securities provided a detailed preview of the industry, expecting revenue growth to be driven by Mergers and Acquisitions (M&A) activity and expansion within India. The firm noted that the Indian Pharma Market (IPM) experienced 12% growth in April/May '26, led by strong performance in the chronic segment at 15% and the acute segment at approximately 10%.
Margin Pressure Loom as Cost Escalation Intensifies
Despite robust revenue potential, HDFC Securities cautioned that EBITDA margins are anticipated to decline year-on-year. This pressure is primarily attributed to escalating costs for inputs and freight. The firm added that increased input costs, coupled with pricing pressures in the US business and steady R&D, will likely impact overall margins this quarter.However, the outlook remains promising for specific segments. HDFC Securities noted that their coverage universe is expected to see a 17% YoY growth in the India business segment. Furthermore, the Contract Research and Development Manufacturing Organization (CRDMO) business within pharma is projected to maintain its existing margins.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.